{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/regulatory-strategy-considerations-advanced-therapies-0#webpage",
"url": "https://www.fortrea.com/insights/regulatory-strategy-considerations-advanced-therapies-0",
"name": "Regulatory strategy considerations for advanced therapies",
"description": "Explore this Fortrea white paper on advanced therapy development across manufacturing and regulatory strategies and discover how integrated planning approaches are helping organizations manage the increasing complexity of cell and gene therapy development across the full product lifecycle. The white paper examines critical considerations involved in advanced therapy development, including manufacturing readiness, chemistry, manufacturing and controls (CMC) planning, regulatory strategy alignment, long-term follow-up (LTFU) requirements, commercialization preparation, and patient journey considerations associated with advanced therapeutics. Learn how integrated development planning, scalable manufacturing strategies, regulatory coordination, long-term patient monitoring, therapy lifecycle management, commercialization readiness, and cross-functional development approaches are supporting the successful advancement of advanced therapies from early clinical development through regulatory engagement, patient access planning, and long-term treatment oversight in rapidly evolving cell and gene therapy programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Regulatory strategy considerations for advanced therapies",
"item": "https://www.fortrea.com/insights/regulatory-strategy-considerations-advanced-therapies-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/regulatory-strategy-considerations-advanced-therapies-0#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/regulatory-strategy-considerations-advanced-therapies-0#webpage"
},
"headline": "Advanced Therapy Manufacturing, Regulatory & Development Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on advanced therapy development across manufacturing and regulatory strategies and discover how integrated planning approaches are helping organizations manage the increasing complexity of cell and gene therapy development across the full product lifecycle. The white paper examines critical considerations involved in advanced therapy development, including manufacturing readiness, chemistry, manufacturing and controls (CMC) planning, regulatory strategy alignment, long-term follow-up (LTFU) requirements, commercialization preparation, and patient journey considerations associated with advanced therapeutics. Learn how integrated development planning, scalable manufacturing strategies, regulatory coordination, long-term patient monitoring, therapy lifecycle management, commercialization readiness, and cross-functional development approaches are supporting the successful advancement of advanced therapies from early clinical development through regulatory engagement, patient access planning, and long-term treatment oversight in rapidly evolving cell and gene therapy programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/advanced-therapies-regulatory-strategy.pdf",
"encodingFormat": "application/pdf"
}
}
]
}